Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Inpatient~* Greater than or equal to (\>=) 18 years of age~* Histologically or cytologically confirmed diagnosis of SCCHN~* Recurrent and/or metastatic SCCHN not suitable for local therapy~* Presence of at least 1 measurable lesion identified either by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified WHO criteria~* Karnofsky performance status (KPS) \>= 80 percent at trial entry~* Neutrophils \>= 1.5\*10\^9 per liter (L), platelet count \>= 100\*10\^9 per L, and hemoglobin \>= 90 gram per liter (g/L)~* Total bilirubin less than or equal to (\<=) 2\*upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<=3\*ULN~* Serum creatinine \<=133 micromole per liter (mcmol/L)~* Serum calcium within normal range~* Effective contraception if procreative potential exists (applicable for both male and female subjects)~Exclusion Criteria:~* Prior systemic chemotherapy, except if given as part of a multimodal treatment which was completed more than 6 months prior to trial entry~* Surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before trial entry~* Nasopharyngeal carcinoma~* Active infection (infection requiring IV antibiotics), including active tuberculosis, or known and declared human immunodeficiency virus (HIV)~* Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, cardiac failure or liver failure~* Uncontrolled hypertension defined as systolic blood pressure \>=180 millimeter of mercury (mmHg) and/or diastolic blood pressure \>=130 mmHg under resting conditions~* Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin \[beta-HCG\] test) or breastfeeding~* Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy~* Other concomitant anticancer therapies~* Documented or symptomatic brain or leptomeningeal metastasis~* Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency~* Medical or psychological condition that would not permit the subject to complete the trial or sign informed consent~* Known drug abuse (with the exception of alcohol abuse)~* Known hypersensitivity or allergic reaction against any of the components of the trial treatment~* Previous treatment with monoclonal antibody therapy, other signal transduction inhibitors or epidermal growth factor receptor (EGFR) targeting therapy~* Previous or current other squamous cell carcinoma (SCC)~* Evidence of previous other malignancy within the last 5 years~* Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such~* Intake of any investigational medication within 30 days before trial entry~* Legal incapacity or limited legal capacity~* Other significant disease that in the Investigator's opinion would exclude the subject from the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Cisplatin + 5-Fluorouracil (5-FU) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete